Pharma giant Novartis and O2 innovation arm Wayra UK revealed last week that Virtue, TestCard and ExSeed would join its nine-month Health Hub accelerator programme.
“After a rigorous judging day, I believe the innovations these three startups offer will make a significant difference to patients and the NHS,” said Novartis Market Access Director Fiona Bride. “I look forward to supporting them over...
The pharma industry has become increasingly interested in the digital health space over the last few years, but this quarter numerous projects that have been in the works for years have finally came to fruition. For instance, Pear's reSET, the first digital therapeutic cleared by the FDA, was recently launched to commercial markets.
But that wasn’t the only advance in the space as pharma...
The FDA has officially cleared reSET-O — a digital therapeutic to treat opioid use disorder (OUD) jointly developed by Pear Therapeutics and Sandoz, a division of Novartis — a little over a year after it was granted an Expedited Access Pathway designation from the agency.
This announcement makes reSET-O the first digital therapeutic to treat patients with OUD. Patients will need a valid...
Novartis' recently-opened digital health innovation lab in San Francisco. Photo courtesy Novartis on Twitter.
Last month, Novartis announced that it would be cutting 2,200 jobs as part of a restructuring of the company focusing on particular priorities.
“The overall strategy we have is to focus the company as a leading medicines company powered by digital technologies,” CEO Vas Narasimhan told STAT News last month. “What that has meant is to exit certain health care sectors or segments … — so we exited...
reSET — a substance use disorder treatment that was the first software-only therapeutic cleared by the FDA — is now commercially available for clinicians to prescribe to their patients, according to a release from Pear Therapeutics and Sandoz, a division of Novartis with which Pear partnered back in April.
But while physical prescription drugs are usually handled through a pharmacy, the process...
NovioSense's artist conception of its device in use.
Last week, Alphabet subsidiary Verily Life Sciences announced the end, at least for the foreseeable future, of its glucose-sensing contact lens collaboration with Novartis.
Verily CTO Brian Otis gave his thoughts in a blog post at the time, stressing the learnings the company got from the project. In a recent interview with MobiHealthNews, Novartis Global Head of Digital Development Jacob LaPorte...
Four years after announcing an ambitious — and often ridiculed — project to create a glucose-sensing contact lens along with Novartis subsidiary Alcon, Alphabet's Verily is throwing in the towel, the company announced in a blog post today. It will continue to work on two other medical contact lens projects, aimed at presbyopia and cataract surgery recovery.
"Our clinical work on the glucose-...
By and large, Q3 2018 was a slow and steady quarter for pharma moves in digital health, at least in terms of publicly disclosed operations. At events during the quarter, the likes of Johnson & Johnson, AstraZeneca, Novartis and Sanofi discussed digital therapeutics and expressed a healthy mixture of skepticism and enthusiasm for the space.
“These technologies have a tremendous opportunity to...
As more and more partnerships between digital therapeutics and pharma companies begin to emerge, the two industries have started to size each other up. While this may foster an exchange of ideas, there is also the danger of concepts getting lost in translation between the two industries.
Yesterday DTx East in Boston pharma execs talked about the future, realities, and challenges of digital...
A recent presentation by headache-focused digital health company Healint and pharma giant Novartis employed Healint’s migraine tracking app Migraine Buddy to look at how migraines interact with anxiety and depression. The research found that chronic migraines may induce anxiety and depression instead of the other way around, contradicting previous thought.
Researchers were able to look at the...
